NASDAQ$HCAT
Health Catalyst Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Health Catalyst's Q2 2024 financial results were reported, demonstrating strong performance with revenue and Adjusted EBITDA exceeding guidance.
Health Catalyst reported strong Q2 2024 financial results, with total revenue of $75.9 million and Adjusted EBITDA of $7.5 million, both exceeding the midpoint of the company's quarterly guidance. The company also saw strong bookings performance, signing more net new Platform Subscription Clients in the first half of 2024 than in all of 2023.
- Total revenue reached $75.9 million, a 4% increase year-over-year.
- Adjusted EBITDA was $7.5 million, a 114% increase year-over-year.
- Net loss improved by 59% year-over-year, coming in at $(13.5) million.
- Signed more net new Platform Subscription Clients in the first half of 2024 than in all of 2023.
Headline financials
Revenue & EPS history
Health Catalyst · Revenue · Quarterly
$75.9M
Revenue by segment
Health Catalyst · $73.8M total across 2 segments · Q3 2023
- Technology$46M+4.5%62.3%
- Professional Services$27.8M+14.1%37.7%
Forward guidance
Health Catalyst provides forward-looking guidance on total revenue and Adjusted EBITDA for Q3 2024 and the full year 2024.
Tailwinds
- Q3 2024 total revenue is expected to be between $74.5 million and $77.5 million.
- Q3 2024 Adjusted EBITDA is expected to be between $6.0 million and $8.0 million.
- Full year 2024 total revenue is expected to be between $304.0 million and $312.0 million.
- Full year 2024 Adjusted EBITDA is expected to be between $24.0 million and $26.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-3.1%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.0%
Avg return
30 days after
41%
11 / 27 earnings
Positive
+27.3%
Q2 2024
Best reaction
-36.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.9% | -21.7% | +4.6% | |
| Q4 2025 | -26.3% | -35.2% | -44.4% | |
| Q3 2025 | -5.6% | -20.5% | -10.2% | |
| Q1 2025 | +5.3% | +8.1% | +3.3% | |
| Q4 2024 | -11.1% | -8.5% | -7.9% | |
| Q3 2024 | +14.2% | +7.2% | +7.6% | |
| Q2 2024 | +27.3% | +7.3% | +22.9% | |
| Q1 2024 | -3.6% | +2.9% | -2.3% | |
| Q4 2023 | -14.7% | -8.9% | -14.4% | |
| Q3 2023 | +5.1% | -0.4% | +5.3% | |
| Q2 2023 | -8.0% | -5.0% | -12.4% | |
| Q1 2023 | -18.9% | -14.8% | -4.3% | |
| Q4 2022 | +7.3% | +5.8% | -14.8% | |
| Q3 2022 | +16.2% | +42.9% | +59.2% | |
| Q2 2022 | -36.6% | -34.7% | -35.9% | |
| Q1 2022 | -2.6% | +24.6% | +10.5% | |
| Q4 2021 | +1.5% | -7.1% | -3.7% | |
| Q3 2021 | -6.2% | -6.1% | -26.9% | |
| Q2 2021 | +1.5% | -2.3% | -2.8% | |
| Q1 2021 | -2.3% | -8.6% | -2.4% | |
| Q4 2020 | +0.6% | +0.1% | -2.1% | |
| Q3 2020 | -0.2% | -3.5% | +6.2% | |
| Q2 2020 | -7.2% | -10.9% | -3.4% | |
| Q1 2020 | -1.9% | -0.5% | -5.0% | |
| Q4 2019 | +1.3% | -5.8% | -20.1% | |
| Q3 2019 | +1.9% | -0.8% | -1.1% | |
| Q2 2019 | -11.5% | -7.8% | -13.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro